1 |
Serum and Glucocorticoid-Regulated Kinase Signaling in Breast CancerGasser, Jessica Ann 04 February 2015 (has links)
Oncogenic activating mutations in PIK3CA, the gene encoding the catalytic subunit of phosphoinositide 3-kinase (PI 3-K), are highly prevalent in breast cancer. The protein kinase Akt is considered to be the primary effector of PIK3CA, though the mechanisms by which PI 3-K mediates tumorigenic signals in an Akt-independent manner remain obscure. My studies show that the serum and glucocorticoid-regulated kinases (SGKs) can function as effectors of PI 3-kinase and transduce signals to phenotypes associated with malignancy. We show that SGK3 is amplified in breast cancer and identify the mechanism by which SGK3 is activated downstream of PIK3CA, specifically through the catalytic activity of the phosphoinositide phosphatase INPP4B. Expression of INPP4B promotes SGK3 activation and in turn inhibits Akt phosphorylation. In breast cancer cell lines with elevated levels of INPP4B, SGK3 is required for proliferation in 3D and also for invasive migration. SGK3 phenotypes are in part mediated by phosphorylation of the substrate protein N-myc downstream regulated 1 (NDRG1), an established metastasis suppressor. The phosphorylation of NDRG1 leads to recruitment by F-box and WD repeat domain-containing 7 (FBW7), the substrate recognition domain of the Skp, Cullin, F-box containing (SCF) complex. Binding of Fbw7 to NDRG1 promotes its polyubiquitination and subsequent degradation by the 26S proteasome. By contrast, our studies also show that the related SGK1 isoform is polyubiquitinated by the functional E3 ubiquitin ligase Rictor-Cullin-1 complex, leading to SGK1 degradation. Proteasomal degradation of SGK1 by Rictor-Cullin-1is the first identified mTORC2-independent function of the Rictor protein. Moreover, the deregulation of SGK1 ubiquitination highlights a mechanism of SGK1 overexpression in breast cancers.
|
2 |
The role of PTEN as a PI(3,4)P2 lipid phosphatase in Class I phosphoinositide 3-kinase signallingKielkowska, Anna Jadwiga January 2018 (has links)
Name: Anna Jadwiga Kielkowska Dissertation title: The role of PTEN as a PI(3,4)P2 lipid phosphatase in Class I phosphoinositide 3-kinase signalling Abstract Class I phosphoinositide 3-kinases (Class I PI3Ks) are essential players involved in the signalling events in the cell and are critical promoters of cellular growth, survival and metabolism. Once activated by environmental stimuli such as growth factors, cytokines or antigens, they exert their catalytic activity by phosphorylating phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2) to yield a second messenger - PI(3,4,5)P3. Unrestrained PI(3,4,5)P3 signalling has been classically associated with hyperactivation of the Class I PI3K/AKT pathway and has been shown to be a molecular trigger of many pathophysiologies in humans, including autoimmune disorders, respiratory diseases and cancer. To date, two classes of lipid phosphatases SHIP1/2 and PTEN have been reported, which dephosphorylate PI(3,4,5)P3 on positions 5’ and 3’ of the inositol ring to generate PI(3,4)P2 and PI(4,5)P2 respectively, and thus quench Class I PI3K signalling. Moreover, PI(3,4)P2 levels in the cell are regulated by two important lipid 4-phosphatases - INPP4A/B. While the role of PTEN as a tumour suppressor is well established, functions of SHIP1/2 and INPP4A/B are just starting to emerge. A major barrier to progress in this field has been the lack of high quality measurements of PI(3,4)P2, to assess the impact it may have on shaping cellular behaviour. This dissertation summarises the work performed to develop a novel, HPLC-ESI MS/MS based method, in order to measure the product of PI(3,4,5)P3 5-dephosphorylation, PI(3,4)P2, separated from its more abundant regioisomer in cells - PI(4,5)P2. This and an existing HPLC-ESI MS/MS method for measuring PI(3,4,5)P3, have enabled us to describe the fluxes through Class I PI3K-controlled PI(3,4,5)P3 generation and its subsequent 3- and 5- dephosphorylation pathways in human mammary epithelial cells (Mcf10a) stimulated with epidermal growth factor (EGF). By means of genetic suppression of PTEN and INPP4B, we revealed an unexpectedly high level of PI(3,4)P2 that accumulates in EGF-stimulated PTEN-INPP4B-KO Mcf10a cells. Further, an in vitro biochemical assay suggested a novel role for PTEN as a direct PI(3,4)P2 3-phosphatase in Mcf10a cells. This important observation was supported by in sillico phosphatidylinositol lipid modelling of the relevant pathways. In an effort to understand its potential physiological significance, we demonstrated that PI(3,4)P2 accumulation correlates with the ability of genetically modified Mcf10a cells to form gelatin-degrading invadopodia. Finally, we used a mouse prostate cancer model to show PTEN’s importance in controlling PI(3,4)P2 levels in vivo, pointing to a potential role for PI(3,4)P2 in PTEN-dependent tumourigenesis. I hope that the work described in this dissertation will contribute to the current knowledge of phosphatidylinositol lipid biology in the context of Class I PI3K signalling and will simulate future efforts to gain an in-depth understanding of the roles of PTEN and PI(3,4)P2 in cellular physiology.
|
Page generated in 0.0333 seconds